Show simple item record

dc.contributor.authorMooranian, Armin
dc.contributor.authorNegrulj, Rebecca
dc.contributor.authorChen-Tan, Nigel
dc.contributor.authorWatts, G.
dc.contributor.authorArfuso, Frank
dc.contributor.authorAl-Salami, Hani
dc.date.accessioned2017-01-30T13:25:17Z
dc.date.available2017-01-30T13:25:17Z
dc.date.created2015-02-01T20:00:57Z
dc.date.issued2014
dc.identifier.citationMooranian, A. and Negrulj, R. and Chen-Tan, N. and Watts, G. and Arfuso, F. and Al-Salami, H. 2014. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Design, Development and Therapy. 214 (8): pp. 1673-1683.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/31430
dc.identifier.doi10.2147/DDDT.S68247
dc.description.abstract

The authors have previously designed, developed, and characterized a novel microencapsulated formulation as a platform for the targeted delivery of therapeutics in an animal model of type 2 diabetes, using the drug probucol (PB). The aim of this study was to optimize PB microcapsules by incorporating the bile acid deoxycholic acid (DCA), which has good permeation-enhancing properties, and to examine its effect on microcapsules’ morphology, rheology, structural and surface characteristics, and excipients’ chemical and thermal compatibilities. Microencapsulation was carried out using a BÜCHI-based microencapsulating system established in the authors’ laboratory. Using the polymer sodium alginate (SA), two microencapsulated formulations were prepared: PB-SA (control) and PB-DCA-SA (test) at a constant ratio (1:30 and 1:3:30, respectively). Complete characterization of the microcapsules was carried out. The incorporation of DCA resulted in better structural and surface characteristics, uniform morphology, and stable chemical and thermal profiles, while size and rheological parameters remained similar to control. In addition, PB-DCA-SA microcapsules showed good excipients’ compatibilities, which were supported by data from differential scanning calorimetry, Fourier transform infrared spectroscopy, scanning electron microscopy, and energy dispersive X-ray studies, suggesting microcapsule stability. Hence, PB-DCA-SA microcapsules have good rheological and compatibility characteristics and may be suitable for the oral delivery of PB in type 2 diabetes.

dc.publisherDove Medical Press Ltd.
dc.subjectartificial cell microencapsulation
dc.subjectanti-inflammatory
dc.subjectprobucol
dc.subjectdiabetes
dc.subjectBÜCHI B390
dc.subjectantioxidant
dc.subjectbile acids
dc.titleAn optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
dc.typeJournal Article
dcterms.source.volume8
dcterms.source.startPage1673
dcterms.source.endPage1683
dcterms.source.issn1177-8881
dcterms.source.titleDrug Design, Development and Therapy
curtin.note

This article is published under the Open Access publishing model and distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by-nc/3.0/ Please refer to the licence to obtain terms for any further reuse or distribution of this work

curtin.departmentSchool of Pharmacy
curtin.accessStatusOpen access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record